FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890393549> ?p ?o ?g. }

• W2890393549 abstract "e14036 Background: Proper assessment of harms of cancer treatment is essential to make risk-benefit trade off decisions in oncology clinic. CONSORT guidelines require the authors of RCTs to provide exact data for adverse events (AEs) grade 3 or higher (severe AEs), serious AEs (SAEs) and fatal AEs (FAEs) and avoid using general terms (such as well-tolerated) that downplay the harms. We aimed to assess the incidence and risks of severe AEs, SAEs and FAEs in such RCTs of cancer drugs that downplayed the harms. Methods: We extracted all the phase 2 and 3 RCTs of cancer drugs from the five major journals (NEJM, Lancet, Lancet Oncology, JAMA, JCO) from 2016 January to 2016 December. The abstracts/full texts of the papers were studied to assess if the harms of the experimental arm were downplayed. Use of any of the following terms while describing toxicities or AEs or safety was assumed to downplay the harms: acceptable, feasible, tolerable (or well-tolerated) , favorable, safe, manageable. Data on severe AEs, SAEs and FAEs for both the experimental and control cohorts were extracted from these RCTs and pooled using random-effects model to determine the overall incidence and risk. Results: Of 122 phase 2/3 RCTs of cancer drugs identified, 53 (43.4%) reports used terms downplaying the toxicities of the experimental arm and were included in this analysis. The overall incidence of severe AEs, SAEs and FAEs with these cancer drugs were 50.6% (95% CI: 41.5%-59.7%), 21.9% (95% CI: 16.3%-28.7%) and 1.6% (95% CI: 1.2%-2.2%) respectively. Compared with control, the risk of severe AEs and SAEs were significantly increased with the use of these cancer drugs: severe AEs (RR 1.15, 95% CI: 1.04-1.27, p = 0.005) and SAEs ( RR 1.49, 95% CI: 1.26-1.77, p < 0.001) . However, the risk of FAEs was similar across the experimental and control arms ( RR 0.89, 95% CI: 0.72-1.11, p = 0.306) Conclusions: Our analysis shows that considerable proportions of patients suffer severe AEs, SAEs and FAEs and significantly increased risk of severe AEs and SAEs in the trials that downplay the toxicities of cancer drugs. Terms that falsely downplay the toxicities of cancer drugs should be avoided in the reporting of RCTs to encourage accurate risk-benefit assessment." @default.
• W2890393549 created "2018-09-27" @default.
• W2890393549 creator A5033279700 @default.
• W2890393549 creator A5035322235 @default.
• W2890393549 creator A5044498054 @default.
• W2890393549 creator A5079533730 @default.
• W2890393549 date "2017-05-20" @default.
• W2890393549 modified "2023-09-27" @default.
• W2890393549 title "The incidence and risks of adverse events in randomized controlled trials (RCTs) of cancer drugs downplaying the harms." @default.
• W2890393549 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14036" @default.
• W2890393549 hasPublicationYear "2017" @default.
• W2890393549 type Work @default.
• W2890393549 sameAs 2890393549 @default.
• W2890393549 citedByCount "0" @default.
• W2890393549 crossrefType "journal-article" @default.
• W2890393549 hasAuthorship W2890393549A5033279700 @default.
• W2890393549 hasAuthorship W2890393549A5035322235 @default.
• W2890393549 hasAuthorship W2890393549A5044498054 @default.
• W2890393549 hasAuthorship W2890393549A5079533730 @default.
• W2890393549 hasConcept C120665830 @default.
• W2890393549 hasConcept C121332964 @default.
• W2890393549 hasConcept C121608353 @default.
• W2890393549 hasConcept C126322002 @default.
• W2890393549 hasConcept C143998085 @default.
• W2890393549 hasConcept C168563851 @default.
• W2890393549 hasConcept C177713679 @default.
• W2890393549 hasConcept C197934379 @default.
• W2890393549 hasConcept C2992704333 @default.
• W2890393549 hasConcept C3020340455 @default.
• W2890393549 hasConcept C61511704 @default.
• W2890393549 hasConcept C71924100 @default.
• W2890393549 hasConceptScore W2890393549C120665830 @default.
• W2890393549 hasConceptScore W2890393549C121332964 @default.
• W2890393549 hasConceptScore W2890393549C121608353 @default.
• W2890393549 hasConceptScore W2890393549C126322002 @default.
• W2890393549 hasConceptScore W2890393549C143998085 @default.
• W2890393549 hasConceptScore W2890393549C168563851 @default.
• W2890393549 hasConceptScore W2890393549C177713679 @default.
• W2890393549 hasConceptScore W2890393549C197934379 @default.
• W2890393549 hasConceptScore W2890393549C2992704333 @default.
• W2890393549 hasConceptScore W2890393549C3020340455 @default.
• W2890393549 hasConceptScore W2890393549C61511704 @default.
• W2890393549 hasConceptScore W2890393549C71924100 @default.
• W2890393549 hasLocation W28903935491 @default.
• W2890393549 hasOpenAccess W2890393549 @default.
• W2890393549 hasPrimaryLocation W28903935491 @default.
• W2890393549 hasRelatedWork W1544091244 @default.
• W2890393549 hasRelatedWork W1574445579 @default.
• W2890393549 hasRelatedWork W1799944587 @default.
• W2890393549 hasRelatedWork W1977820044 @default.
• W2890393549 hasRelatedWork W1979129627 @default.
• W2890393549 hasRelatedWork W2013709680 @default.
• W2890393549 hasRelatedWork W2034797162 @default.
• W2890393549 hasRelatedWork W2325004728 @default.
• W2890393549 hasRelatedWork W2330502900 @default.
• W2890393549 hasRelatedWork W2336355222 @default.
• W2890393549 hasRelatedWork W2416084933 @default.
• W2890393549 hasRelatedWork W2589139957 @default.
• W2890393549 hasRelatedWork W2908120283 @default.
• W2890393549 hasRelatedWork W2908845694 @default.
• W2890393549 hasRelatedWork W2919260334 @default.
• W2890393549 hasRelatedWork W2944325031 @default.
• W2890393549 hasRelatedWork W3133596586 @default.
• W2890393549 hasRelatedWork W3149969615 @default.
• W2890393549 hasRelatedWork W3163530790 @default.
• W2890393549 hasRelatedWork W3184972978 @default.
• W2890393549 isParatext "false" @default.
• W2890393549 isRetracted "false" @default.
• W2890393549 magId "2890393549" @default.
• W2890393549 workType "article" @default.